Mirae Asset Global ETFs Holdings’s Vir Biotechnology VIR Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Buy	196,778 +83,440	+74%	+$794K	﹤0.01%	1242
2026 Q1	$1.01M	Buy	113,338 +6,361	+6%	+$50.7K	﹤0.01%	1521
2025 Q4	$644K	Buy	106,977 +1,012	+1%	+$6.03K	﹤0.01%	1764
2025 Q3	$605K	Buy	+105,965	New	+$542K	﹤0.01%	1779
2025 Q2	–	Sell	-193,378	Closed	-$1.25M	–	3245
2025 Q1	$1.25M	Sell	193,378 -3,402	-2%	-$30.2K	﹤0.01%	1381
2024 Q4	$1.44M	Buy	196,780 +7,110	+4%	+$56.1K	﹤0.01%	1348
2024 Q3	$1.42M	Sell	189,670 -29,490	-13%	-$256K	﹤0.01%	1340
2024 Q2	$1.95M	Buy	+219,160	New	+$2.1M	﹤0.01%	1091

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's VIR Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Vir Biotechnology (VIR) stake by 74% in Q2 2026, buying an estimated $794K and bringing the position to 196,778 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Mirae Asset Global ETFs Holdings first reported a position in VIR in Q2 2024 and has held it in 8 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Mirae Asset Global ETFs Holdings held 196,778 shares of Vir Biotechnology worth $2.01M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 83,440 Vir Biotechnology shares in Q2 2026, an estimated $794K.
Vir Biotechnology made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1242 holding.
Mirae Asset Global ETFs Holdings first reported a position in Vir Biotechnology in Q2 2024 and has held it in 8 quarters since.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.